glp 1 agonists long term effects GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes

Study: GLP 1s 'hold promise' for treating a wide range of diseases and health outcomes Comparing Ozempic, Wegovy and Other GLP 1 Drugs GoodRx Comparative effectiveness of SGLT2 inhibitors, GLP 1 receptor agonists, DPP 4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records The Lancet DeBakey Glucagon like peptide 1 (GLP 1) receptor agonists are currently the most effective pharmacologic strategy for the treatment of obesity. Table 1 lists incretin based therapies and their indications, side effects, contraindications, etc "Medical Understanding the Difference: While both peptides are powerful metabolic tools, their pharmacology is distinct: Tirzepatide (Manjaro): This is a dual agonist targeting GLP 1 (Glucagon like peptide 1) and GIP (Glucose dependent insulinotropic